Risankizumab is a monoclonal antibody used in the treatment of autoimmune conditions, particularly moderate to severe plaque psoriasis and psoriatic arthritis. Risankizumab selectively targets interleukin-23 (IL-23), a cytokine involved in the inflammatory pathway that drives autoimmune diseases such as psoriasis. By blocking IL-23, risankizumab helps to reduce inflammation and the abnormal skin cell growth associated with psoriasis. It is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Risankizumab is also used for the treatment of active psoriatic arthritis in adults who have not responded adequately to other treatments.